Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04778982CT.gov Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer | — | Terminated | — | — | — |
NCT05076695CT.gov Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer | — | Unknown | — | — | — |
NCT04360941CT.gov PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT04288089CT.gov A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03644186CT.gov To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) | — | Completed | — | — | — |
NCT03530696CT.gov T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer | — | Completed | — | — | — |
NCT03709082CT.gov Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01037790CT.gov Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · HER2 Positive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Palbociclib (this asset) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | P2 | B · 62 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Trastuzumab | SWOG Cancer Research Network | P4 | BB |
| Ribociclib | Danish Breast Cancer Cooperative Group | P3 | BB |
| Vinorelbine Ditartrate | Fudan University | P3 | BB |
| Cyclophosphamide | National University Hospital, Singapore | P3 | BB |
| Capecitabine | MedSIR | P4 | BB |
| Docetaxel | Ohio State University Comprehensive Cancer Center | P3 | BB |
| Carboplatin | Rutgers, The State University of New Jersey | P3 | BB |
+42 more in the HER2 Positive Breast Carcinoma cohort
Other indications for Palbociclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 75 |
| Hormone Receptor-Positive Breast Cancer | — | P3 | BBB · 73 |
| Breast Cancer | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Palbociclib in HER2 Positive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/palbociclib-her2-positive-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →